Novavax (NVAX) Reports Positive Phase 1 Data for COVID-19 Vaccine Candidate
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate
August 4, 2020 4:06 PM EDTPhase 1 portion of the Phase 1/2 clinical trial evaluated two doses of Novavax COVID-19 vaccine across two dose levels (5 and 25 µg) in 131 healthy adults ages 18-59 yearsNVX-CoV2373 was generally well-tolerated and had a reassuring safety profileThe vaccine induced neutralization titers in 100% of participants Both 5 µg and 25 µg adjuvanted doses generated peak geometric mean titer (GMT) greater than 1:3,300 Matrix-M adjuvant induced robust polyfunctional CD4+ T cell responsesConference call to be held on Tuesday,... More
